Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 1 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 1 | 1 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0012 | 0.3523 | 0.3523 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 1 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 1 | 0.5 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0019 | 1 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 1 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 1 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 1 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 1 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 1 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 1 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0012 | 0.3523 | 0.3523 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 1 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0019 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 1 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0012 | 0.3523 | 0.3523 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0019 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.